Measles virus vaccine induces oncolysis of tumor cells and activates immune responses.
|
|
- Janice Holmes
- 6 years ago
- Views:
Transcription
1 Measles virus vaccine induces oncolysis of tumor cells and activates immune responses. Marc Grégoire*, J.-F. Fonteneau, N. Boisgerault, J.-B. Guillerme and F. Tangy. * INSERM, Nantes, F-44, France. Pasteur Institute, Viral Genomics and Vaccination, Paris, France
2 Anti-tumor Virotherapy using oncolytic virus Infection apoptosis Activation of the immune system Oncolytic virus Infection Tumor cells Healthy cells Ideal replicating oncolytic virus: Russell SJ, Nature biotechnol, 212 Vacchelli E et al, Oncoimmunology, Infects exclusively or preferentially tumor cells - Kills efficiently tumor cells (apoptosis) - No toxicity (genetically stable, minor side effects) - High viral concentration production capability - Induction or stimulation of an anti-tumor immune response.
3 Measles virus vaccine () based anti-tumoral virotherapy Hémagglutinine (H) Protéine de Fusion (F) Protéine de Matrice (M) Protéine L Phosphoprotéine (P) ARN + Nucléoprotéine (N) Double membrane lipidique Guillerme JB et al, Biology, 213 Measles virus vaccine, Schwarz strain (): Dr Frédéric Tangy (Viral genomics and Vaccination laboratory, Pasteur Institut, Paris) - Enveloped, non-segmented, negative-sense, single-stranded RNA (ssrna) paramyxovirus of the genus Morbillivirus - Attenuated replicating vaccine strain of measles virus: Schwarz (MMR vaccine) - Targets CD46, complement regulatory protein (wt targets CD15/SLAM) - CD46 is expressed at low level by healthy cells - CD46 is often found overexpressed on tumor cells - antiviral pathway defects are often found in tumor cells - Spontaneously oncolytic: - Lymphoma, glioma, breast, ovary, prostate (Russell SJ, Mayo Clinic, USA) - MPM, colon and lung adenocarcinoma Gauvrit A et al, Cancer Research, 28; Boisgerault N et al, Biomed Res Int, 213
4 Oncovirotherapy Oncolytic properties of Measles Vaccine Tumour Cell Oncolytic properties Immunogenic apoptotic cell death Virus Oncolytic (Vaccine strain) immunogenic molecules DAMP & PAMP Specific T cell response T Lymphocytes Myéloïd DC Plasmacytoïd DC
5 % egfp + cells Tumour cell infection (mesothelioma) INFECTION Mesothelioma Infected cells -egfp Others Mesothelioma : 14/18 Melanoma : 7/8 Lung : 3/4 Colorectal : 4/ Meso11 Meso13 Meso47 Meso56 Meso Time post infection (h) Syncitium Mesothelioma (Gauvrit A et al, Cancer Research, 28) Lung, Colorectal adenocarcinoma (N. Boisgerault et al., Biomed. Res. Int., 213)
6 Normal cells: mesothelial and lung cells Mesothelial cells Lung cells Also for : Fibroblasts Endothelial cells
7 Oncovirotherapy - Live attenuated Schwarz Measles Vaccine Tumour Cell Oncolytic properties Immunogenic apoptotic cell death Virus Oncolytic (Vaccine strain) immunogenic molecules DAMP & PAMP Specific T cell response T Lymphocytes Myéloïd DC Plasmacytoïd DC
8 Median Fluorescence Intensity HMGB1 (ng/ml) % Calreticulin + cells Danger Signals: Damage Associated Molecular Patterns Bianchi and Manfredi, 27 Kepp et al., 29 HSP7 Cross-presentation of tumor-derived antigens HMGB1 Antigen processing and presentation Calreticulin Phagocytosis Control Meso13 A549 M6 HT29 Meso13 A549 M6 HT29 Meso13 ADK153 M6 HT29 Gregoire et al, in preparation
9 Immune response with Live attenuated Schwarz Measles Vaccine Tumour Cell Oncolytic properties Immunogenic apoptotic cell death Virus Oncolytic (Vaccine strain) immunogenic molecules DAMP & PAMP Specific T cell response Activation maturation T Lymphocytes Myéloïd DC Plasmacytoïd DC
10 preserves dendritic cells Mo-DC pdc Myeloid dendritic cells (Gauvrit A et al., 28, Cancer Research) Plasmacytoid dendritic cells (Guillerme JB et al., 213, Clinical Cancer Research)
11 -infected tumor cells induced Mo-DC Maturation MFI MFI IFNα - PolyI:C TNFα - PolyI:C MFI MFI IFNα - PolyI:C TNFα - PolyI:C MFI % CD83 + cells IFNα - PolyI:C TNFα - PolyI:C 2 CMH I HLA-A,B,C 2 CD8 CD8 1 CD83 CD Dci IFN TNF M11 UV HLA-DR M11 CMH II M13 UV M13 6 Dci IFN TNF M11 UV M11 CD86 CD86 M13 UV M13 1 Dci IFN TNF M11 UV M11 CD4 CD4 M13 UV M DCi Dci IFN TNF UV M11 UV M11 UV M13 UV M13 Meso 11 Meso 13 DCi Dci IFN TNF UV M11 UV M11 UV M13 UV M13 Meso 11 Meso 13 DCi Dci IFN TNF UV M11 UV M11 UV M13 UV M13 Meso 11 Meso 13 (Gauvrit A et al., 28, Cancer Research)
12 % CD8+ IFN- + cpm cpm MUC-1 or mesothelin +Mo-DC 1 T CD4 Proliferation CD4 4 T CD8 Proliferation CD DCi IFN -PolyI:C UV DCi IFN -PolyI:C UV Meso 13 Meso 13 Clone T CD8 anti-muc-1 Cross-presentation (mesothelin) 1 5 DCi TNFα- PolyI:C (Gauvrit A et al., 28, Cancer Research) Meso 13 (Gauvrit et al., 28)
13 Plasmacytoid dendritic cells Expression of TLR7 et TLR9 => specialized in recognition of viral nucleic acids ARNsb Produce huge quantities of Type I IFN (- and b) in response to virus Antigen cross presentation in human: HIV (Hoeffel, G,.Immunity, 27) (Crozat, K., J Exp Med, 21) Influenza (Lui, G., PLoS One, 29) Antigen cross presentation in mice: Cross-tolérance (Goubier, A., Dubois, B., Immunity, 28) OVA (Mouries, J., Blood, 28) One of the target of imiquimod (R837, TLR7 ligand) in the treatment of basal cell carcinoma with Aldara. IFN- Production and tumor antigen cross-presentation by pdc exposed to infected tumor cells?
14 PKH67 PKH67 infected tumor cells are internalized by Plasmacytoid dendritic cells Mo-DC pdc 4 C 37 C 4 C 37 C HLA-DR Alexa568 PKH-67 MERGE M18 UV pdc + M18 A549 pdc + A549 UV HLA-DR BDCA-4
15 IL3 +IL3 R848 M18 M18 UV Meso13 Meso13 UV A549 A549 UV R-MFI SSC CD123 IL3 +IL3 R848 M18 M18 UV Meso13 Meso13 UV A549 A549 UV IL3 +IL3 R848 M18 M18 UV Meso13 Meso13 UV A549 A549 UV % Positive Cells R-MFI infected tumor cells induce Plasmacytoid dendritic cells maturation FSC BDCA4 CD83 CD86 CD4 CD83 CD86 IL3 9 % 4, *** ** *** ** *** 2 15 * R % 13, % 5,13 1 IL % 5, * CD4 15 Meso % 12, Meso13 UV 7.42 % 5,33 22
16 IL3 IL3 + R848 M18 M18 UV A549 A549 UV IFN- (ng/ml) pdc IFN-α (ng/ml) IFN- (ng/ml) infected tumor cells induce production of INF type I by pdc IL-3 IL-3,1,1,5,1,5,1,5 1,5 1,1,1,5,5 1,1,1,5,5 1 IRS661 IRS661 IRS661 IRS661: TLR7inhibitor IL-3 IL-3 + *1 *1 CpG-A CpG-A M18 CpG-A CpG-A (TLR-9)
17 CD8 CD8 CD8 CD8 LT only (n=5) pdc + LT (n=6) pdc.1 µm NYESO-1 (n=3) pdc + M18 (n=6) pdc + M18 UV(n=5) % of IFN + T CD8+ cells CD8 CD8 infected tumor cells induce NY-ESO-1 cross-presentation by pdc LT only pdc+ LT.1%.1% IFN-γ IFN-γ LT + pdc.1µm NYESO-1 [ ] 1µM NYESO-1 [ ] 1.8% 87.5% R % UV.2% 1 M18.8%.2% A549 IFN-γ LT - pdc IFN-γ M18 M18 UV.3%.1% IFN-γ IFN-γ
18 In conclusion: Virotherapy and DC activations Tumor cells Apoptosis Dendritic cells Cytotoxic CD8+ T Lymphocytes (CTL) Dangers signal expression HMGB1 Calreticuline HSP inflammasome, caspase1, IL-1b Boisgerault N et al, in preparation Immune system activation Activation of myeloïd DC Activation of tumor antigen specific CD8+ T lymphocytes Gauvrit A et al, Cancer Research, 28 Immune system activation Activation of plasmacytoid DC (production of type I interferon) Guillerme JB et al, Clin. Cancer Res., 213
19 IMMUNOGENIC PROPERTIES OF DEAD CELLS CANCER RESEARCH CENTER, NANTES, FRANCE MARC GREGOIRE JEAN-FRANÇOIS FONTENEAU ANNE GAUVRIT JEAN-BAPTISTE GUILLERME NICOLAS BOISGERAULT VIRAL GENOMICS AND VACCINATION LABORATORY PASTEUR INSTITUTE, PARIS, FRANCE FRÉDÉRIC TANGY MARIANA MESEL-LEMOINE DEVELOPMENT AND CLINICAL TRANSFER CORE FACILITY PLATFORM DELPHINE COULAIS CLARISSE PANTERNE
Immunoadjuvant Properties of Oncolytic Schwarz Measles Virus
Immunoadjuvant Properties of Oncolytic Schwarz Measles Virus Dr Jean-François Fonteneau Institut de Recherche en Santé de l Université de Nantes INSERM UMR892, CNRS UMR6299 Nantes, France Anti-tumor Virotherapy
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationIntrinsic cellular defenses against virus infection
Intrinsic cellular defenses against virus infection Detection of virus infection Host cell response to virus infection Interferons: structure and synthesis Induction of antiviral activity Viral defenses
More informationReplicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.
Replicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.6P Frédéric Tangy Viral Genomics and Vaccination Laboratory Measles
More informationSupplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast
Supplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast carcinoma (a) and colon adenocarcinoma (b) were staining
More information2. Innate immunity 2013
1 Innate Immune Responses 3 Innate immunity Abul K. Abbas University of California San Francisco The initial responses to: 1. Microbes: essential early mechanisms to prevent, control, or eliminate infection;
More informationInnate immunity. Abul K. Abbas University of California San Francisco. FOCiS
1 Innate immunity Abul K. Abbas University of California San Francisco FOCiS 2 Lecture outline Components of innate immunity Recognition of microbes and dead cells Toll Like Receptors NOD Like Receptors/Inflammasome
More informationImmunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008
Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell
More informationAntibodies for human plasmacytoïd dendritic cells studies Dendritics SAS, 60 avenue Rockefeller, F Lyon
Antibodies for human plasmacytoïd dendritic cells studies Dendritics SAS, 60 avenue Rockefeller, F-69008 Lyon www.dendritics.net Human plasmacytoïd dendritic cells (PDCs) are considered the main sentinels
More informationLAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies
LAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies Cancer immunotherapy has emerged as a clinically validated tool for fighting certain kinds of cancers. These therapeutic cancer vaccines
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationTowards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Your logo Natural control of HIV infection is associated with an isotype switched IgG antibody response to HIV Gag antigens in patients with
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationEffector Mechanisms of Cell-Mediated Immunity
Effector Mechanisms of Cell-Mediated Immunity Dr. Julia Rempel Section of Hepatology 789-3825 jdrempel@cc.umanitoba.ca 804D JBRC Topics: I. Types of Cell-Mediated Immunity II. Migration of Effector T Lymphocytes
More informationAGAINST VIRAL INFECTIONS. Identify the types of immunity involve in the mechanisms of protection against viral infections.
LECTURE: 02 Title: THE IMMUNOLOGICAL PROTECTIVE MECHANISMS AGAINST VIRAL INFECTIONS LEARNING OBJECTIVES: The student should be able to: Identify the types of immunity involve in the mechanisms of protection
More informationRichard S. Kornbluth, M.D., Ph.D.
Treatment of established tumors with peritumoral injections of CD40 ligand (CD40L), CpG, poly(i:c), and extracellular ATP in murine models Richard S. Kornbluth, M.D., Ph.D. Disclosure: Richard Kornbluth
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationDendritic Cell Based Immunotherapy for Cancer. Edgar G. Engleman, M.D.
Dendritic Cell Based Immunotherapy for Cancer Edgar G. Engleman, M.D. Two main DC subsets Myeloid (mydc) Derived from monocytes Capture/process/present Ag to T cells Activate NK cells and B cells Plasmacytoid
More information7/6/2009. The study of the immune system and of diseases that occur as a result of inappropriate or inadequate actions of the immune system.
Diseases of Immunity 2009 CL Davis General Pathology Paul W. Snyder, DVM, PhD Purdue University Acknowledgements Pathologic Basis of Veterinary Disease, 4 th Ed Veterinary Immunology, An Introduction 8
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationTCR, MHC and coreceptors
Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationVIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON
VIRUSES Biology Applications Control David R. Harper GS Garland Science Taylor & Francis Group NEW YORK AND LONDON vii Chapter 1 Virus Structure and 2.2 VIRUS MORPHOLOGY 26 Infection 1 2.3 VIRAL CLASSIFICATION
More informationInnate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin
Chapter Know Differences and Provide Examples Innate Immunity kin and Epithelial Barriers Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive Immunity
More informationLecture on Innate Immunity and Inflammation
Lecture on Innate Immunity and Inflammation Evolutionary View Epithelial barriers to infection Four main types of innate recognition molecules:tlrs, CLRs, NLRs, RLRs NF-κB, the master transcriptional regulator
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More informationThe next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)
The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold
More informationInnate Immunity. Jan 8 th Prof. dr. sc. Ivana Novak Nakir 1
Innate Immunity Jan 8 th 2018. Prof. dr. sc. Ivana Novak Nakir 1 Adaptive Innate 2 Immune system overview 1 st line of defense skin (2m 2 ) and mucosal membranes (~400m 2 ): physical barrier, lymphoid
More informationInnate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin
Know Differences and Provide Examples Chapter * Innate Immunity * kin and Epithelial Barriers * Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive
More informationLecture on Innate Immunity and Inflammation. Innate Immunity: An Evolutionary View
Lecture on Innate Immunity and Inflammation Evolutionary View Epithelial barriers to infection Four main types of innate recognition molecules:tlrs, CLRs, NLRs, RLRs NF-κB, the master transcriptional regulator
More informationImmunology. T-Lymphocytes. 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters,
Immunology T-Lymphocytes 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters, karin.peters@rub.de The role of T-effector cells in the immune response against microbes cellular immunity humoral immunity
More informationInnate Immunity & Inflammation
Innate Immunity & Inflammation The innate immune system is an evolutionally conserved mechanism that provides an early and effective response against invading microbial pathogens. It relies on a limited
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationEmerging Viruses. Part IIb Follow Up from Part I Vaccines and Inhibitors
Emerging Viruses Part IIb Follow Up from Part I Vaccines and Inhibitors Cellular Responses to Viral Invasion: Restriction Factors Cells fight viral infection using a series of restriction factors Restriction
More informationJustus Hallam Iowa State University. Iowa State University Capstones, Theses and Dissertations. Graduate Theses and Dissertations
Graduate Theses and Dissertations Iowa State University Capstones, Theses and Dissertations 2013 Exercise-mediated changes in plasmacytoid dendritic cell production of IFNα and the effects of moderate
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationRole of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D.
Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D. Biology Lead Toronto Centre for Liver Disease Toronto General Hospital Research Institute University Health Network (UHN) HBV
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationCampbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions
Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System 24.1 Multiple-Choice Questions 1) The body's innate defenses against infection include A) several nonspecific
More informationThe Role of Plasmacytoid Dendritic Cells in Psoriasis
6 ème Journée du Groupe de Recherche sur le Psoriasis Paris, 9 novembre 2012 The Role of Plasmacytoid Dendritic Cells in Psoriasis Dr Curdin Conrad, PD & MER Department of Dermatology Psoriasis: Clinical
More information1. The scavenger receptor, CD36, functions as a coreceptor for which TLR? a. TLR ½ b. TLR 3 c. TLR 4 d. TLR 2/6
Allergy and Immunology Review Corner: Cellular and Molecular Immunology, 8th Edition By Abul K. Abbas, MBBS, Andrew H. H. Lichtman, MD, PhD and Shiv Pillai, MBBS, PhD. Chapter 4 (pages 62-74): Innate Immunity
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In the manuscript Rational Combination of CXCL11-Expressing Oncolytic Virus and PD-L1 Blockade Works Synergistically to Enhance Therapeutic Efficacy
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationEbola virus crisis. Prof. Viktor Volchkov. Molecular basis of viral pathogenicity
Ebola virus crisis Prof. Viktor Volchkov Molecular basis of viral pathogenicity International Centre for Research in Infectiology (CIRI), INSERM Claude Bernard University Lyon-1, Lyon, France viktor.volchkov@inserm.fr
More informationOncolytic virus strategy
Oncolytic viruses Oncolytic virus strategy normal tumor NO replication replication survival lysis Oncolytic virus strategy Mechanisms of tumor selectivity of several, some of them naturally, oncolytic
More informationIntracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining Btk activation Xingguang Liu, Zhenzhen Zhan, Dong Li, Li Xu, Feng Ma, Peng Zhang, Hangping Yao and Xuetao
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More informationCell-mediated Immunity
Cellular & Molecular Immunology Cell-mediated Immunity Nicholas M. Ponzio, Ph.D. Department of Pathology & Laboratory Medicine April 6, 2009 Today s Presentation: Overview Cellular Interactions In Humoral
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationSupplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses.
Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses. Percentage of viable (A) pdcs (Sytox Blue-, Lin1-, HLADR+, BDCA2++)
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationStructure and Function of Antigen Recognition Molecules
MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and
More informationCANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University
CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More information10th International Rotavirus Symposium Bangkok, Thailand
Rotavirus Host Range Restriction and Innate Immunity: Mechanisms of Vaccine Attenuation Harry Greenberg MD Stanford University 10th International Rotavirus Symposium Bangkok, Thailand 09/19/12 B dsrna
More informationExperimental Therapeutics I
Experimental Therapeutics I Mary Hitt 5142 Katz Group Centre mhitt@ualberta.ca; or Mary.Hitt@albertahealthservices.ca 1 Specific Topics for Today Preclinical and clinical testing Gene therapy Nonviral
More information1. TLR. TLR Toll-like receptors. Toll Toll-like receptor, TLR TLR TLR TLR. type I TLR TLR. Toll
54pp.145 152 2004 1. TLR T B TLR Toll-like receptors TLR TLR I IFN TLR T B B T Toll NF- B 1996 565-0871 3-1 TEL 06-6879-8303 FAX 06-6879-8305 E-mail uemattsu@biken.osaka-u.ac.jp Toll Toll-like receptor,
More informationVaccines. Prof. Lana E. Kandalaft. Director Centre of Experimental Therapeutics, Deparment of Oncology, UNIL CHUV
Vaccines Prof. Lana E. Kandalaft Director Centre of Experimental Therapeutics, Deparment of Oncology, UNIL CHUV Assisant Professor, Ludwig Cancer Reaserch Branch Adjunct Assistant Professor, University
More informationLecture 9: T-cell Mediated Immunity
Lecture 9: T-cell Mediated Immunity Questions to Consider How do T cells know where to go? Questions to Consider How do T cells know where to go? How does antigen get targeted to a T cell expressing the
More informationVaccine Delivery and TLR Ligands Influence the Quality of T cell Responses in NHP. Robert A. Seder, M.D. Vaccine Research Center NIAID, NIH
Vaccine Delivery and TLR Ligands Influence the Quality of T cell Responses in NHP Robert A. Seder, M.D. Vaccine Research Center NIAID, NIH Vaccines Against HIV, Malaria and Tuberculosis Will Require Neutralizing
More informationMicro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier
Micro 204 Cytotoxic T Lymphocytes (CTL) Lewis Lanier Lewis.Lanier@ucsf.edu Lymphocyte-mediated Cytotoxicity CD8 + αβ-tcr + T cells CD4 + αβ-tcr + T cells γδ-tcr + T cells Natural Killer cells CD8 + αβ-tcr
More informationInnate Immunity, Inflammation and Cancer
Innate Immunity, Inflammation and Cancer Willem Overwijk, Ph.D. Melanoma Medical Oncology Center for Cancer Immunology Research MD Anderson Cancer Center, Houston, TX SITC/MDACC -6/14/2013 www.allthingsbeautiful.com
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationnumbe r Done by Corrected by Doctor
numbe r 5 Done by Mustafa Khader Corrected by Mahdi Sharawi Doctor Ashraf Khasawneh Viral Replication Mechanisms: (Protein Synthesis) 1. Monocistronic Method: All human cells practice the monocistronic
More informationHIV Immunopathogenesis. Modeling the Immune System May 2, 2007
HIV Immunopathogenesis Modeling the Immune System May 2, 2007 Question 1 : Explain how HIV infects the host Zafer Iscan Yuanjian Wang Zufferey Abhishek Garg How does HIV infect the host? HIV infection
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Cytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Understand the physiological
More informationCYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.
More informationVasoactive intestinal peptide inhibits IFN-α secretion and modulates the immune function of plasmacytoid dendritic cells
Excerpt from MACS&more Vol 12 1/21 Vasoactive intestinal peptide inhibits IFN-α secretion and modulates the immune function of plasmacytoid dendritic cells Dorit Fabricius 1, 2,, M. Sue O Dorisio 1, 2,
More informationQuestion 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell?
Abbas Chapter 2: Sarah Spriet February 8, 2015 Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell? a. Dendritic cells b. Macrophages c. Monocytes
More informationInnate Immunity and Inflammation
SITC Primer on Tumor Immunology and Biological Therapy of Cancer Innate Immunity and Inflammation Willem Overwijk, Ph.D. MD Anderson Cancer Center Center for Cancer Immunology Research Houston, TX www.allthingsbeautiful.com
More informationImpact of TLR7/8 Triggering on HIV Pathogenesis
University Hospital Zurich u Division of Infectious Diseases and Hospital Epidemiology Impact of TLR7/8 Triggering on HIV Pathogenesis Roberto F. Speck, MD Hallmark of HIV-Infection is the Progressive
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationViruses. CLS 212: Medical Microbiology Miss Zeina Alkudmani
Viruses CLS 212: Medical Microbiology Miss Zeina Alkudmani History Through the 1800s, many scientists discovered that something smaller than bacteria could cause disease and they called it virion (Latin
More informationCancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
More informationImmune surveillance: The immune system can recognize and destroy nascent malignant cells
Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor
More information5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
More informationJPEMS Nantes, Basic Immunology INNATE IMMUNITY
JPEMS Nantes, 2014- Basic Immunology INNATE IMMUNITY Teacher: Pr. Régis Josien, Laboratoire d Immunologie and INSERM U1064, CHU Nantes Regis.Josien@univ-nantes.fr 1 Contents 1. General features and specificity
More informationVpu Reduces Innate Sensing of HIV-1-infected cells by PDCs via a BST2-dependent process
Vpu Reduces Innate Sensing of HIV-1-infected cells by PDCs via a -dependent process Mariana G. Bego, Édouard Bérubé-Côté, Johanne Mercier, and Éric A. Cohen Institut de Recherches Cliniques de Montréal.
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationInnate Immunity. Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 2 August 2016
Innate Immunity Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 2 August 2016 Objectives: Explain how innate immune system recognizes foreign substances
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationBases for Immunotherapy in Multiple Myeloma
Bases for Immunotherapy in Multiple Myeloma Paola Neri, MD, PhD Associate Professor of Medicine University of Calgary, Arnie Charbonneau Cancer Institute Disclosures Paola Neri MD, PhD Grants/research
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationCell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC)
Chapter 16 CELL MEDIATED IMMUNITY Cell Mediated Immunity Also known as Cellular Immunity or CMI The effector phase T cells Specificity for immune recognition reactions TH provide cytokines CTLs do the
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationOncolytic viruses: a new class of immunotherapy drugs
CANCER IMMUNOTHERAPY Oncolytic viruses: a new class of immunotherapy drugs Howard L. Kaufman, Frederick J. Kohlhapp and Andrew Zloza Abstract Oncolytic viruses represent a new class of therapeutic agents
More informationSignificance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationCBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology
CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development
More informationImmune Surveillance. Immune Surveillance. Immune Surveillance. Neutrophil granulocytes Macrophages. M-cells
he immune system is everywhere Some organs have developed strategies towards the immune system to keep it out or to put it under control Immune privileged organs: Brain Eye estis hyroid gland Humoral immunity
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationHarnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms
Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms (the language of immunology) Barbara K. Dunn NCI/Division of Cancer Prevention October 23, 2017 Harnessing the Immune System
More information